Cholesterol Metabolism and Regulation

Cholesterol is an essential membrane sterol and the precursor of steroid hormones, bile acids, and vitamin D. Its cellular and whole-body levels are held within tight limits by a feedback system that balances de novo synthesis, receptor-mediated uptake from circulating lipoproteins, and export, with HMG-CoA reductase serving as the rate-limiting and pharmacologically central enzyme.

Definition

Cholesterol metabolism is the integrated set of pathways governing cholesterol synthesis (the mevalonate pathway from acetyl-CoA, controlled by HMG-CoA reductase), its uptake into cells through LDL receptors, its conversion to bile acids and steroids, and its export, all coordinated by sterol-sensing feedback that adjusts synthesis and uptake to maintain a stable sterol pool.

Scope

The entry covers the biosynthetic pathway from acetyl-CoA to cholesterol, the regulation of HMG-CoA reductase, the SREBP-SCAP-INSIG sensing system, receptor-mediated LDL uptake, and the principles of reverse cholesterol transport. It is a biochemical and physiological reference and does not provide guidance on managing cholesterol levels in individuals.

Core questions

• What is the rate-limiting step of cholesterol synthesis and how is it controlled?
• How do cells sense sterol levels and adjust synthesis and uptake accordingly?
• How does receptor-mediated endocytosis of LDL deliver cholesterol to cells?
• How is excess cholesterol returned from peripheral tissues to the liver?

Key concepts

• Mevalonate pathway
• HMG-CoA reductase (rate-limiting enzyme)
• SREBP, SCAP, and INSIG sterol sensing
• LDL receptor and receptor-mediated endocytosis
• Reverse cholesterol transport and HDL
• Bile acid and steroid hormone synthesis
• Statins as HMG-CoA reductase inhibitors

Key theories

Receptor-mediated feedback control of cholesterol

Brown and Goldstein showed that cells take up cholesterol through the LDL receptor and that the resulting sterol load feeds back to suppress both endogenous synthesis and further receptor expression, defining the central homeostatic loop of cholesterol balance.

SREBP-SCAP-INSIG sterol-sensing switch

When membrane sterols fall, the SCAP escort protein releases SREBP from the endoplasmic reticulum to the Golgi for proteolytic activation, turning on cholesterol and fatty acid synthesis; rising sterols retain the complex through INSIG, shutting the program off.

Mechanisms

Cholesterol is built through the mevalonate pathway: acetyl-CoA units form HMG-CoA, which HMG-CoA reductase reduces to mevalonate in the committed, rate-limiting step, followed by a series of condensations producing squalene and ultimately cholesterol. The cell monitors its sterol content through the SCAP-INSIG system in the endoplasmic reticulum: low sterols allow SCAP to escort SREBP to the Golgi, where proteases release the active transcription factor that induces HMG-CoA reductase and the LDL receptor; high sterols retain the complex and also accelerate reductase degradation, providing tight feedback. Cells obtain additional cholesterol by LDL receptor-mediated endocytosis, the pathway Brown and Goldstein defined. Surplus peripheral cholesterol is effluxed to HDL and returned to the liver for excretion as bile acids (reverse cholesterol transport). Statins act by competitively inhibiting HMG-CoA reductase, lowering intracellular sterol and thereby upregulating LDL receptors.

Clinical relevance

Cholesterol metabolism underlies the biology of atherosclerosis, familial hypercholesterolemia (caused by LDL receptor defects), and the mechanism of statin drugs, and it provides the basis for understanding bile acid and steroid hormone production. This entry describes normal regulation and pharmacological targets for reference and education; it is not a guide to diagnosing or treating dyslipidemia in any individual.

History

Konrad Bloch and Feodor Lynen mapped the long biosynthetic route from acetate to cholesterol in the mid-twentieth century, work recognized by the 1964 Nobel Prize. Brown and Goldstein then defined the LDL receptor pathway and its feedback control in the 1970s and 1980s, earning the 1985 Nobel Prize, and their later identification of the SREBP-SCAP-INSIG system explained the molecular sterol sensor. In parallel, Akira Endo's discovery of the first statins translated HMG-CoA reductase inhibition into therapy.

Key figures

• Michael Brown
• Joseph Goldstein
• Konrad Bloch
• Feodor Lynen
• Akira Endo

Seminal works

• brown-goldstein-1986
• brown-goldstein-1999
• horton-2002

Frequently asked questions

What is the rate-limiting enzyme of cholesterol synthesis?

HMG-CoA reductase, which converts HMG-CoA to mevalonate, is the committed and rate-limiting enzyme; it is the target of statin drugs and is tightly regulated by cellular sterol levels.

How do cells avoid making too much cholesterol?

A sterol-sensing system (SCAP-INSIG-SREBP) suppresses both cholesterol synthesis and LDL receptor expression when intracellular sterols are high, and accelerates degradation of HMG-CoA reductase, providing feedback control.